16 February 2017
Atlas Genetics has said it will expand manufacturing capacity for cartridgebased STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.
Atlas announced it would increase capacity at Bespak’s facility in King’s Lynn, Norfolk last week, explaining it will pay for the expansion with some of the £28.4m ($35.5m) it raised through a recent Series D fundraising round.
UK-based Atlas Genetics – which has received a second equity investment from Bespak’s owner Consort Medical plc in a series D financing round – develops in vitro diagnostic tests for sexually transmitted infections.
In addition to funding the manufacturing expansion, funds raised during the investment round will finance clinical trials and commercial launch of a combined Chlamydia and Gonorrhoea test Atlas is developing.
Marc Green, spokesperson for Atlas Genetics, told inPharmatechnologist the expansion at the King’s Lynn facility will support commercial launch.
The firm anticipates US and EU regulatory approval for the tests by end of 2017.
Jonathan Glenn, Consort Medical CEO, said: “We are excited about the potential for this rapid testing technology, and remain committed as Atlas Genetics’ development and manufacturing partner through our Bespak subsidiary.”
King’s Lynn
Bespak’s site in King’s Lynn has also been employed for manufacturing use by Big Pharma firms GSK and AstraZeneca.
The facility is equipped with clean rooms with injection moulding machines and automated assembly suites.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
mRNA cancer vaccine granted world-first approval
13 May 2024
Life expectancy of Russians citizens should reach 81 years by 2036
13 May 2024
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024